Advisory - Isotechnika to Announce Clinical Data From Phase III Psoriasis Trial

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will announce
preliminary 48 week clinical trial data for the Company's Canadian
Phase III psoriasis trial for its lead immunosuppressive drug,
ISA247, on Monday, March 20th at 8:00 a.m. EST/6:00 a.m. MST.

Management will provide an overview of the preliminary 48 week
Phase III data following the release at 9:00 a.m. EST/ 7:00 a.m.
MST. All interested parties will be able to access the live web cast
(listen only mode) through our corporate Web site at
www.isotechnika.com.

About Isotechnika Inc.

----------------------

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247, is an immunosuppressant
currently in an extension protocol of a Canadian Phase III human
clinical trial for the treatment of moderate to severe psoriasis. In
addition, ISA247 has successfully completed a Phase IIa trial for
kidney transplantation. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93, which is in
Phase I.

In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(R) and Diatest(R)
breath kits. The Helikit(R), a 13C urea breath test, is used for the
detection of H. pylori, a bacterium that infects a large portion of
the population. The Diatest(R), a 13C glucose breath test, is used
to measure insulin resistance.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to
the potential of its products, the Company's expectations regarding
the issuance of additional patents and the Company's ability to
protect its intellectual property, involve known and unknown risks
and uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialise its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

Trades on Toronto Stock Exchange - (TSX: ISA)

www.isotechnika.com

Archived images on this organisation are searchable through CNW
Photo Archive website at http://photos.newswire.ca. Images are free
to accredited members of the media.

To request a free copy of this organisation's annual report,
please go to http://www.newswire.ca and click on Tools for
Investors.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., Phone: +1-780-909-4661,
Fax: +1-780-484-4105, E-mail: sgillis-paulgaard@isotechnika.com